John P. Bilello

TL;DR: Hamsters infected with SARS-CoV-2 expressing spike D614G (G614 virus) produced higher infectious titres in nasal washes and the trachea, but not in the lungs, supporting clinical evidence showing that the mutation enhances viral loads in the upper respiratory tract of COVID-19 patients and may increase transmission.

TL;DR: The pathogenic lymphocryptovirus Epstein–Barr virus (EBV) is shown to express at least 17 distinct microRNAs (miRNAs) in latently infected cells, seven of which are closely related to EBV miRNAs.

TL;DR: Remdesivir (RDV) potently inhibits SARS-CoV-2 replication in human lung cells and primary human airway epithelial cultures and in mice infected with chimeric virus, supporting its further clinical testing for treatment of COVID-19.

TL;DR: A high-throughput nanoluciferase severe respiratory syndrome coronavirus 2 (SARS-CoV-2-Nluc) that is genetically stable and replicates similarly to the wild-type virus in cell culture is presented and can be used for antiviral screening.

TL;DR: Cl cloning and analysis of microRNAs encoded by Rhesus Monkey Rhadinovirus, an animal virus model for the pathogenic human gamma-herpesv virus Kaposi's Sarcoma-Associated Herpesvirus, set the stage for the mutational ablation and phenotypic analysis of RRV mutants lacking one or more viral micro RNAs.